Despite the risk of missing mutations, oncologists predominantly use convenient, less-invasive liquid biopsies to test for biomarkers at disease progression. A more invasive tissue biopsy is generally reserved for situations where the cancer behaves unexpectedly, such as a sudden shift from bone-only to visceral disease, which might suggest a missed biological driver.
Clinicians increasingly perform Next-Generation Sequencing (NGS) on initial diagnostic tissue, even if results don't alter first-line treatment. This proactive approach identifies stable mutations like PIK3CA early, enabling long-term planning, such as optimizing a patient's metabolic health in anticipation of future targeted therapies.
Large real-world databases show elacestrant monotherapy achieves a median time-to-next-treatment of over 8 months. This impressive outcome aligns with the most favorable subgroup from the pivotal EMERALD trial (patients on prior CDK4/6i >12 months), suggesting that clinicians are successfully identifying the ideal candidates for this therapy in routine practice.
While PI3K pathway alterations are linked to a poor prognosis, real-world data provides reassurance for a common clinical dilemma. Patients with co-mutations in both ESR1 and PI3K pathways still achieve significant benefit from elacestrant monotherapy, with progression-free survival (5.2-6.3 months) comparable to the overall population in the pivotal EMERALD trial.
For patients with both ESR1 and PIK3CA mutations, emerging data suggests prioritizing an oral SERD-based combination. The EMBER-3 trial showed imlunestrant plus abemaciclib achieved a ~12-month PFS in this subgroup, starkly outperforming the ~5.6-month PFS seen with PI3K/AKT inhibitor combinations like capivasertib-fulvestrant in the CAPItello-291 trial.
Data from multiple trials (EMERALD, VERITEC-2) reveal that the duration of a patient's response to a prior CDK4/6 inhibitor acts as a key predictive biomarker. Patients who benefited from CDK4/6 inhibitors for longer periods (e.g., >12-18 months) subsequently experienced a significantly greater progression-free survival benefit from oral SERD therapy.